COVID-19 Hits Merck KGaA's MS Drug Mavenclad
Fertility Franchise Also Impacted
Executive Summary
The lockdowns caused by coronavirus has led to significant decline of multiple sclerosis patients getting to see neurologists and getting treatment. It has also reduced the number of treatment switches and Merck's drug Mavenclad is suffering as a consequence.